MedTrace Logo

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

NCT06490328 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2026-08-14

No results posted yet for this study

Summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Conditions

Interventions

DRUG

DKF-MA102

Administered twice at 12-week intervals

Sponsors & Collaborators

  • Dongkook Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Choung-Soo Kim, M.D.,Ph.D · Ewha Womans University Mokdong Hospital

  • Jae Young Joung, M.D.,Ph.D · Center for Prostate Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408, Republic of Korea

  • Sung Kyu Hong, M.D.,Ph.D · Department of Urology, Seoul National University Bundang Hospital, 82, Gumi-ro, 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Korea

  • Seong Soo Jeon, M.D.,Ph.D · Department of Urology, Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul 135-710, Korea

  • Cheol Kwak, M.D.,Ph.D · Department of Urology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

  • Kyo Chul Koo, M.D.,Ph.D · Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

  • Bumjin Lim, M.D. · Department of Urology, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea

  • Ji Youl Lee, M.D.,Ph.D · Department of Urology, Seoul Saint. Mary's Hospital, 222 Banpo-daero, Seocho-gu, Seoul 06591, South Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2026-01-21
Completion
2026-03-09

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490328 on ClinicalTrials.gov